PURPOSE; To summarize current knowledge of interventions that should improve the care of patients with type II diabetes meUitus. Interventions lie within the realms of prevention, screening, and treatment, all of which are focused on office practice.
could include differences in disease severity, comorbidi ties. or access to care, Diabetes has significmlt associated morbidity, Prevention and treatment of the complications of diabetes mellitus have the potential to improve quality of life and increase life expectancy, s The rate of cardiovascular disease is markedly elevated among patients with type II dta betes, leading to an increased mortality rate compared with the general population, 4,c' In addition, microvascular complications, which include retinopathy, nephropathy, and neuropathy, can progress to end-stage outcomes such as blindness, end-stage renal disease (ESRD), and amputation. Screening and early treatment for diabetic complications have been shown to be effective in reducing the incidence of end-stage disease~J: despite this evidence. implementation rates of recommended interventions are low/ This frequently leads to ineffective or delayed treatment of complications, '#11 Because optimal diabetes care is a complex process, we developed a clinical care guideline to help busy clinicians incorporate prevention, screening, and treatment recommendations into practice,
METHODS
A multidisciplinary team was assembled to develop an evidence-based guideKne for the prevention and treatment of complications of type II diabetes. The multidisciplinary team included members from endocrinolo~, family practice, general internal medicine, obstetrics-gyncecology, nursing, and postgraduate medicine departments. Team members have an interest in diabetes care. are experts in diabetes care, or have experience with guideline development.
The consensus of the guideline development team was that preventive mid screening measures should constitute the main focus of the guideline, There was uniform agreement that the two major complications of type II diabetes were macrovascular and microvascular disease. Preliminary evidence reviewed for guideline development included studies on type II diabetes felt to be important by the mem bers of the guideline team. Consensus statements from expert panels on hypertension, lipids, and diabetes were examined, and the references from these statements were reviewed. Other literature was identified by metals of a sys-567
PREVENTION AND TREATMENT OF MACROVASCULAR DISEASE
Atllerosclerotic disease, commonly referred to as "macrovasculaff' disease, is responsible for more than 5&Yo of all mortality in type II diabetes mellitus. 1 Type II diabetes is an independent risk factor for tile development of atllerosclerosis. 1: The majority of atherosclerotic macrovascular complications are due to cardiovascular disease, 4.5 with the remaining complications related to cerebral vascular or peripheral vascular disease. The pathogenesis of the in creased rate of atherosclerosis in patients with type II dia betes is not completely defined: the relation between hyperinsulinemia, hyperglycemia, and atheroselerotie dis ease is an area of continuing controversy, zs-:~ The United Kingdom Prospective Diabetes Study (UKPDS). a large ongoing trial evaluating the efficacy of improved glycemic control in preventing macrovascular disease, ~l may clarify the relation between insulin levels, glycemic control, and atherosclerosis. Factors such as hypertension, hyperlipid emia, and tobacco use clearly contribute to the risk of macrovascular disease in patients with type II diabetes, Therefore, the prophylactic use of aspirin, control of hy pertension and hyperlipidemia, and cessation of smoking are particularly important in patients with type II diabetes mellitus.
Prophylactic Use of Aspirin
Meta analysis and a large, randomized, controlled trial reveal that people with diabetes receive the same cardiovascular protection from aspirin as nondiabetic pa tients. ~.~3 Aspirin use in diabetic patients is not associ ated with an increased rate of adverse effects as compared with the general population. ~3 Although not all of the dig ferences in outcomes measured in these studies achieve statistical significance, there is a trend among all aspirintreated groups to have lower cardiovascular event rates and mortality. Therefore, we recommend preventive use of aspirin in patients with type II diabetes mellitus who are aged 50 years or older and/or have other cardiovascular risk factors, ~4 provided no contraindications are present.
Althougll specific dosages have not been compared in clinical trials, the recommended dosage ranges between 81 rng (1 baby aspirin) and 325 rng/day.
Hypertension
Hypertension is a significant contributor to the development of atherosclerotic disease in patients with type II diabetes mellitus. ~s Untreated hypertension can also lead to worsening of albuminuria and more rapid decline of the glomerular filtration rate. :s Therefore, screening and treat ment of hypertension are important components of diabe tes care, Persons with type II diabetes develop hypertension at twice the rate of those without diabetesY .~s There are ra cial differences in the prevalence of hypertension, with African Americans having the highest rates of hypertension, followed by whites, Hispanics, and Asians. ~' -~ Data from the National Health and Nutrition Examination Survey II (NHANES II) show that the prevalence of people with dia betes mellitus with hypertension increases with age: more than 60o/0 of diabetic patients over 45 A = randomized controtled trials B -eOntlC~lled trims, no randomization C = ebservationM tams D = opinion of expr pane] *studies in general population **studies in patients with diabetes FIGURE 1. Screening, prevention, and healment of cardiovascular risk factors in palients with h/pe II diabetes mellitus: hypertension, hyperlipidemia, and smoking. toms of hypoglycemia (although this is rarely a problem in type II diabetics) and may decrease high-density lipoprotein (HDL) and increase triglyceride levels, z; ~,l-Adrenerglc receptor blockers do not have adverse glycemic or lipid effects, but may aggravate postural hypotension in some persons with diabetes, c'~.
Studies reveal that 20% to 6(YYo of patients are not sufficiently controlled on monotherapy. 4~ In these cases, combination therapy of an ACE inhibitor with a low-dose thiazide diuretic works well, and seems to ameliorate the metabolic problems seen with either treatment alone, at least in nondiabetic subjects, Some studies of the combination of an ACE inhibitor with a calcium channel blocker demonstrate greater benefits than either agent alone. ~'" The combination of l~-blocker with a thiazide can lead to an increase in plasma glucose levels and should be used with caution/n,rl
Lipids
Characteristically, persons with type II diabetes have el evated triglyceride mid very-low-density lipoprotein (VLDL) levels, while HDL levels are low, Low-density lipoprotein levels can also be elevated, e':,e's Hyperlipidemia contributes significmltly to the development of atherosclerotic disease in patients with type II diabetes/~ However. no trials identifying treatment target levels for HDL and LDL in patients with type II diabetes have been completed, In addition. optimal cholesterol screening intervals have not been determined for patients with diabetes. In high risk, nondia betic populations, rmldomized, controlled trials demonstrate that lowering LDL leads to a reduction in cardiovascular mortality, e'4,~5 Because of the high prevalence of coronary artery disease (CAD) in diabetic patients, the National Cholesterol Education Panel (NCEP) recommends that diabetic patients be screened annually and treated like patients with known CAD, with treatment initiated at an LDL level above 130 mg/dL with an LDL goal of less than 100 mg/dL/' Although 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors are effective in lowering LDL levels/v,r~ long-term benefit has not been evaluated in patients with type II diabetes. Clinical data are limited, but screening for hyperlipidemia and treatment of elevated lipid subfractions in patients with diabetes have the potential to similarly reduce cardiovascular morbidity and mortality. Thus, although studies have not been per formed that specifically evaluate patients with diabetes. because of their markedly elevated cardiovascular risk. we recommend treating diabetic patients with elevated LDL levels according to the NCEP guidelines, The first line of therapy is dietary intervention, followed by the use of HMG CoA reductase inhibitors when necessary to achieve target LDL levels ( Fig. 1 ), Nicotinic acid should be used with caution as it may worsen hyperglycemia, r''"
In patients with diabetes, triglycerides are an inde pendent risk factor for the development of atherosclerotic disease/~,rs Initial therapy should consist of improving glycemic control with a combination of exercise, dietary changes, and increased intensity of oral hypoglycemics or insulin, If these changes are ineffective, then pharmacologic therapy with gemfibrozil should be considered if the triglyceride level remains greater thin1 400 mg/dL/~,r~',rn Genffibrozil has been shown to be effective in lowering the rate of cardiovascular, but not overall, mortality in the general population, 71 Subgroup analysis suggests that patients with type II diabetes may receive greater benefit from treatment of hypertriglyceridemia: however, the num ber of patients studied was small and differences were not statistically significant/s Until better evidence is available for individuals with type II diabetes mellitus, we recom mend an unproven yet conservative approach of aggressive dietary intervention mid glycemic control followed by gemfibrozil (when necessary) for hypertriglyceridemia.
Smoking
Longitudinal cohort studies have shown that smok ing and diabetes are synergistic risk factors for the devel opment of atherosclerotic disease, iS,T; Patients with diabetes should be counseled regarding these risks, and all possible measures should be used to prevent and encour age discontinuation of tobacco use (Fig, 1) . This includes enrollment in formal smoking cessation programs and use of alternative nicotine delivery systems when neces sary, The use of nicotine patches is safe in patients with known cardiovascular disc ase. 7s
PREVENTION AND TREATMENT OF MICROVASCULAR DISEASE
Diabetes is the leading cause of new cases of blind ness. renal failure, and nontraumatic amputation in the United States,1 These outcomes are frequently the result of progression of microvascular diabetic complications in cluding retinopathy, nephropathy, and neuropathy. The risk of developing these complications can be significmltly reduced by interventions that prevent the onset or slow the progression of early microvascular disease.
Retinopathy
In type I diabetes, randomized, controlled trials have demonstrated that improving glycemic control can decrease the incidence of diabetic retinopathy, 74 Observational studies in patients with type II diabetes suggest a similar relation between level of glycemic control and rate of retinopathy. ~c, ~ Primary prevention of diabetic retinopathy, therefore, consists of optimization of giycemic con trol, In addition, improving glycemic control slows the progression of retinopathy in patients who have already developed background retinopathy. 74 Progression of diabetic eye disease to proliferative retinopathy and macular edema frequently leads to severe visual loss. Multicenter randomized controlled trials have shown that laser therapy of proliferative retinopathy and macular edema significantly reduces the incidence of visual loss in patients with diabetes. ~-J Despite the demon strated effectiveness of laser therapy, it is estimated that only 35% to 600/0 of diabetic patients currently undergo annual retinal examination, s While less frequent screen ing may be indicated for those considered to be at low risk of developing retinopathy. ~ such as those without retinopathy at baseline and those with excellent glycemic control, formal risk-stratification based on these clinical indicators has not yet been widely implemented,
Studies that have evaluated the sensitivity and speci ficity of retinal screening show that primary care clinicians trained to perform dilated retinal examinations can detect proliferative retinopathy, but fail to consistently de tect macular edema. ~* Although the optimal frequency of screening has not been evaluated by randomized con trolled trials, we suggest that all patients undergo mmual dilated retinal examination by a trained specialist (Fig. 2) . Laser therapy for proliferative retinopathy and macular edema should be performed by trained ophthalmologists.
Nephropathy
As with retinopathy, optimization of glycemic control acts as primary prevention of diabetic nephropathy. 74.77 Aggressive control of hypertension mid ACE inhibitor therapy play a vital role in prevention of renal disease.
Microalbuminuria and proteinuria have been identi fled to be early signs of diabetic nephropathy. 7'" Although optimal screening intervals have not been determined. screening for early diabetic renal disease can allow inter ventions that lower the rate of progression to overt nephropathy and ESRD, 44,45 The current recommended method of screening for early stages of diabetic nephropathy is ou~ lined in Figure 2 , This algorithm is based on the level of albumin excretion, Causes of elevated urinary albumin excretion in the absence of diabetic nephropathy include urinary tract infection, recent exercise, acute illness, hematuria. and congestive heart failure, It is recommended that urine be screened for hematuria, urinary tract infection, and overt diabetic nephropathy with a standard urine dipstick test prior to screening for early nephropathy, Overt diabetic nephropathy is classified as a protein positive (1+ or greater) urine dipstick test. which represents macroalbuminuria, or an albumin concentration of greater than 300 rng/g creatinine. This equates to approxi mately 300 mg of albumin excretion per day/n Dipstick tests that are negative or show positive traces of protein should be followed with screening for early diabetic ne phropathy, commonly referred to as microalbuminuria.
There are numerous methods of screening for microalbuminuria. The spot urinary albumin creatinine ra tio is a simple method that negates concerns about measurement errors inherent in 24-hour collections, Because of significant variation in urinary albumin concentration, it is recommended that. if the first test for albumin is positive (>30 mg/g creatinine), the test be repeated for confirmation. If the second test is negative, a third test should be performed, Two of the three tests should be positive, and other potential etiologies should be excluded before microalbuminuria is considered present (Fig. 2) .
A clinical diagnosis of diabetic nephropathy may be made when an individual develops albuminuria and either has had diabetes for more than 5 years or has evi dence of diabetic retinopathy/1 Because other complicating renal diseases may also cause albuminuria, a person who does not meet one of the above criteria or has factors suggestive of other renal diseases (such as active urinary sediment, nephrotic-range proteinuria, accelerated hypertension, or rapidly progressive renal insufficiency) will re quire further evaluation. Dietary protein restriction appears to slow the pro gression of renal disease in patients with type I diabetes. In type II diabetes, however, protein restriction has not been consistently demonstrated to be effective in prevent ing the progression of early nephropathyd a
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Neuropathy and Foot Care
Patients with diabetes are at increased risk of devel oping peripheral neuropathy and diabetic foot ulcers. Dia betic neuropathy is reported in more than 50% of patients who have had type II diabetes for more than 15 years. 1 Improving glycemic control reduces the incidence of neu ropathy in type I diabetes, ~4 and the epidemiologic literature suggests a similar association in type II diabetes. 77.e3
Evidence indicates that early detection of diabetic neurop athy results in fewer admissions for foot ulcers and amputations, e4 As shown in Figure 4 , sensory testing with nylon monofilament (10 g) should be done regularly to identify sensory loss at appropriate anatomic landmarks of the foot. e5 The optimum interval between such exam| nations has not been determined, but many experts ad vise mmual testing 9
The combination of patient education regarding foot care and increased surveillance by physicians regarding foot-related risk factors for amputation has been exam|ned in a randomized, controlled trial and a cohort trial, s~. (Fig. 2) ,
We r e c o n m l e n d , at e a c h r e g u l a r visit, t h a t p a t i e n t s with d i a b e t e s h a v e t h e i r feet i n s p e c t e d . The foot e x a m i n a tion s h o u l d also include identifying a r e a s of callus formation. deformities, i n c l u d i n g p r o m i n e n t m e t a t a r s a l h e a d s (or o t h e r b o n y p r o m i n e n c e s ) a n d o t h e r s t r u c t u r a l c h a n g e s . O r t h o t i c f o o t w e a r s h o u l d be p r e s c r i b e d to a c c o m m o d a t e m a j o r foot d e f o r m i t i e s a n d c u s h i o n p r e s s u r e areas: t h e r ap e u t i c footwear for d i a b e t i c p a t i e n t s is a Medicare benefit. For o t h e r s w i t h less deformity, athletic s h o e s w i t h suffic i e n t r o o m for the t o e s a n d forefoot w i t h c u s h i o n e d s o c k s are a p p r o p r i a t e . P a t i e n t s w i t h a b n o r m a l foot e x a m i n a t i o n n e e d e d u c ation r e g a r d i n g optimal foot care. w h i c h i n c l u d e s daily ins p e c t i o n b y the p a t i e n t a n d a p p r o p r i a t e l y fitting s h o e s , e~-To m i n i m i z e the r i s k of t r a u m a , p a t i e n t s s h o u l d be c o u ns e l e d to avoid w a l k i n g barefoot, a n d t h o s e w i t h n e u r o p at h y s h o u l d avoid h i g h i m p a c t exercise a n d s h o u l d t e s t t h e t e m p e r a t u r e of h o t w a t e r before use, A n u m b e r of d r u g s are c u r r e n t l y u n d e r i n v e s t i g a t i o n for the t r e a t m e n t of dia betie n e u r o p a t h y , i n c l u d i n g a l d o s e r e d u e t a s e i n h i b i t o r s (JARls), w h i c h b l o c k the c o n v e r s i o n of glucose to sorbitol a n d nerve g r o w t h factors. R e c e n t e v i d e n c e i n d i c a t e s t h a t the new, m o r e p o t e n t ARIs p r o m o t e n
e r v e fiber r e g e n e r ation a n d p r e v e n t slowing of n e r v e c o n d u c t i o n velocity in diabetic n e u r o p a t h y , e' -~.' -~~ T h e s e d r u g s are not y e t available for u s e in t h e U n i t e d States, Painful diabetic n e u r o p a t h y can be m a n a g e d with low dose tricyclic a n t i d e p r e s s a n t s , with the dose titrated as nec essary. Careful a t t e n t i o n s h o u l d be paid to the etiology of painful lower extremities, a s m e c h a n i c a l factors, r a t h e r t h a n n e u r o p a t h y , are often the cause, a n d m a y r e s p o n d to m e d 5 cations s u c h as nonsteroidal mlti-inflammatory d r u g s , '1 A diabetic foot ulcer is defined as a n y i n t e r r u p t i o n of the integrity of the skin t h a t e
x t e n d s t h r o u g h the entire dermis, S h o u l d a foot u l c e r be found, early t r e a t m e n t s h o u l d be u n d e r t a k e n w i t h aggressive w o u n d care, orthotic p r e s c r i p t i o n s or c a s t i n g , p r e s s u r e relief, a n d a n t i b i o t i c s a s n e c e s s a r y , '"~ The i n d i c a t i o n s for a n t i b i o t i c s t r e a t m e n t of d i a b e t i c foot u l c e r s h a v e n o t b e e n well defined. S t u d i e s h a v e s h o w n t h a t p a t i e n t s with diabetic foot u l c e r s h a v e the b e s t o u t c o m e s if m m l a g e d b y a m u l t i d i s c i p l i n a r y t e a m w h i c h s p e c i a l i z e s in diabetic foot care. ' -~3

Glycemic Control
The Diabetes Control a n d 
t i o n a l s t u d i e s in p a t i e n t s w i t h type II d i a b e t e s mellit u s have s h o w n t h a t level of glycemic control is a s s o c i a t e d w i t h the d e v e l o p m e n t of m i c r o v a s c u l a r diabetic c o m p l i c ations, zr'J7 A single r a n d o m i z e d , controlled trial of J a p an e s e p a t i e n t s w i t h type II d i a b e t e s h a s c o n f i r m e d t h a t the rate of m i c r o v a s c u l a r c o m p l i c a t i o n s c a n be r e d u c e d by i m p r o v i n g levels of glycemic c o n t r o l a s m e a s u r e d b y he-
* Get the patient comfortable and relaxed. , Show the patient the filament and touch his or her hand with it to show that it doesn't hurt. -Ask the patient to say "yes" when he or she feels the filament on the loot. Don't ask, *'Do you feel that?" * Hold the filament perpendicular to lhe skin and use a smooth motion: touch until the filament bends, then lift oft', Don't jab or bounce around. o Touch designated parts of Ihe feet randomly so Ihe patient can't guess where the next point will be. Most critical are the great toe and the ball of the foot. -If the patient doesn't say "yes'* when you touch a particular spot, go to another site and come back to that one later. 9 Keep the filament in its plastic case at all times when not in use. It can be cleaned with sodium hypoehlorite 1:10 solution.
. Jr. This is a public document. The center is no longer in existence. (Fig, 3 and Table 2 ). Several factors must be considered for each patient when selecting glyce mic target levels. Foryoung, healthy patients, the possibil ity of eventually developing advmmed complications (e,g,. blindness, ESRD) should be of major concern, and in gen eral, tight control should be advocated, However. in the presence of Factors that affect the benefit and risk of glycemic control, it is less clear whether tight control is worth the associated risk and lifestyle modification, As depicted in Table 2 , target glucose levels for patients with type II diabetes must be individually determined based on factors that affect the risk-benefit ratio of tight control. The actual target level of glycemic control selected for each person with type II diabetes mellitus must represent a balance among the patient's self-determined diabetes care goals.
the likelihood of benefit from attaining those goals, and the risks associated with the therapy required to achieve those goals. Once a glycemic target has been established, adjustments in diet and, if necessary, medications should be made until the target has been reached, Targets need to be reassessed on a regular basis, as the circumstances of each patient will change over time.
Glycemic Management
Diet and exercise are the cornerstones for the man agement of hyperglycemia in type II diabetes mellitus, Patients who do not achieve adequate glycemic control with an individualized meal plan and exercise program are can didates for pharmacologic therapy. Pharmacologic treatment options include oral administration of a sulfonylurea, a biguanide (metformin), c~ glucosidase inhibitor (acarbose), a thiazolidinedione (troglitazone), and subcutaneous insulin. Even after pharmacologic therapy is instituted, careful attention must be paid to diet and activity.
Diet and Meal Plans
Meal planning for people with type II diabetes represents both first line therapy and a cornerstone of their ongoing care. Although weight loss has traditionally been the primary focus of meal planning for people with type II diabetes, current dietary strategies and even very low cat orie diets have not generally been effective in achieving long-term weight reduction. '~ Therefore. it is recommended that medical nutrition therapy in type II diabetes emphasize achieving glucose, lipid, and BP goals. ' -~e There is no one "diabetic" diet, The diet currently recommended by the American Diabetes Association is de fined as a dietary prescription based on a nutrition assess ment and designed to help the patient reach treatment goals. '-~e Ongoing medical nutrition therapy provided by a dietitian is effective for achieving metabolic and other clinical outcomes in type II diabetes, '*~ Referral to a dietitian is recommended at diagnosis and annually. 100
Moderate weight loss by persons with type II diabetes can reduce hyperglycemia, dyslipidernia, and hypertension, even when desirable body weight is not achieved. 1ol-1o3 It is currently recommended that providers emphasize reason able rather than ideal or desirable body weights.in4 Rea- Comorbidities (e.~., end-sta~e cancer, congestive heart failure) Advanced diabetes complications (e.~., proliferative retinopathy, ESRD) Inability to carry out treatment re_Nmen (e,g., financial constraints, availability of needed supplies) IAmited life expectancy History of severe hypoglycemia (inability to treat without assistance):
any episodes within the past year and/or more than 2 episodes ever Hypoglycemia unawareness Advanced cardiovascular or cerebrovas~flar disease Autonomic neuropathy (especially cardiac) Comorbidities/medications that impair the detection of hypo~ycemia (e.~., B-blockers, CNS-actin~ dru~s, alteration in mental status) Lack of mobility or lives alone
Based on expert opinion, sonable body weight is defined as the weight that is viewed by the individual with diabetes and the health care team as one that is achievable and maintainable both short and long teiTn. For some individuals, even those who are overweight, this may be current weight or a weight 5 to 10 kg less than the current weight.i~
Other strategies such as spacing of meals through out the day. ~'~c'n'": regular exercise. :~ and learning new behaviors z~ can facilitate weight management and metm bolic control. No one meal planning method can be uni fomfly recommended for all people with type II diabetes, A nutritionally adequate meal plan focused on achieving metabolic and other goals cml be provided using a healthy food-choices approach, the exchange system, or carbohydrate counting, ss
Sulfonylureas
Traditionally, sulfonylureas have been used as first line therapy for patients with NIDDM in whom nonpharmacologlc therapy has failed, xo_~ Today the shorte~acting second generation sulfonylureas are preferred over the earlier agents, such as chlonpropamide, which could cause hypoglycemia that was prolonged. Sulfonylureas act pri marily by increasing pancreatic insulin secretion, but may also increase insulin receptor sensitivity. 1~o Patients may be treated with a sulfonylurea starting at a low dose that can be increased as necessary at weekly intervals until satisfactory glycemic control is achieved or the highest recommended dose is reached. If the patient has not achieved his or her glycemic goal at a maximal sulfonyl urea dose. combination therapy with metformin, acarbose, or insulin should be considered.
Biguanides
Meffom~l, a bigumlide, may also be selected as a first-line pharmacologic treatment for patients with NIDDM in whom nonpharmacologlc therapy has failed, iiMi: Met fom3in lowers blood glucose by increasing peripheral in sulin sensitivity and decreasing hepatic glucose production. lie Metformin should be avoided in patients with renal hepatic, or cardiac failure. Gastrointestinal side ef fects, including anorexia, nausea, diarrhea, and abdominal discomtbrt, are seen in up to 30% of patients. A begin ning metformin dose of 500 mg per day will reduce these side effects and may be increased by 500 mg per week to a maximum dose of 2.5 g per day. If the patient has not achieved his or her glycemic goal at the mmximum meb folTnin dose. combination therapy or a change to insulin should be considered.
ot-Glucosidase Inhibitor
(~ Glucosidase inhibitors such as acarbose may also be used as monotherapy in conjunction with diet to lower blood glucose, xx4 Acarbose slows the digestion of ingested carbohydrates, delays glucose absorption into the blood stream, mid decreases postprandial blood glucose. The initial dose is 25 mg three times a day mid should be taken with the first bite of each main meal. Oastrointesti hal side effects including pain. flatulence, and diarrhea are conmlon: although these effects usually diminish over time (4~8 weeks), they frequently lead to discontinuation of the drug. Some experts advocate starting at a lower dose (25 mg once a day) to minimize the initial side effects and increase compliance, The maintenance dose may be titrated to 50 to 100 mg three times per day, us
Thiazolidinediones
The thiazolidinediones are a new class of oral agents designed to enhance the actions of insulin, lls Troglita zone, the first drug in this class marketed in the United States. is currently approved for use in patients with type II diabetes on insulin therapy whose hyperglycemia is in adequately controlled despite multiple daily injections. To date. troglitazone has not been approved for use as a monotherapy or in combination with other oral agents, al though studies are ongoing and it may be approved for broader indications in the near future.
Thiazolidinediones lower blood glucose levels by im proving sensitivity to insulin in muscle and adipose tissue. and by inhibiting hepatic glucose production, Short-temi trials in patients with type II diabetes have demonstrated reductions in fasting and postprandial glucose levels and insulin levels. Troglitazone has been associated with liver function abnormalities, slight reductions in hemoglobin and white cell counts, possibly related to dilutional effects, and resumption of ovulation in premenopausal anovulatory patients with insulin resistance (polycystic ovary syndrome). The latter patients may be at risk of pregnmlcy, xlsnx7 Tro glitazone is usually started at a dose of 200 mg/d. and over 2 to 4 weeks can be titrated to 400 mg/d. The maxi mal dose is 600 mg/d. Caution should be used when ti trating as troglitazone, in combination with insulin, can produce hypoglycemia; the dosage of insulin should be re duced by 10% to 25% when the fasting blood glucose falls to less than i20 mg/dL.
Bedtime Insulin/Daytime Sulfonylurea Therapy
Bedtime insulin/daytime sulfonylurea (BIDS) therapy may be considered for patients who do not achieve glyce mic goals despite maximum doses of oral agents, ns Met fomfin is discontinued, and the patient is continued on daytime sulfonylurea at a maximum dose. Selflmonitor ing of blood glucose is intensified and NPH insulin is added at bedtime, The usual starting dose of insulin is 0.3 units/kg of body weight with ongoing adjustment of therapy to achieve glycemic goals. In the Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes, a mean insulin dose of 64 units was required to achieve glyeemie goals in patients who were able to remain on BIDS therapy, :n
Insulin
If combination therapy falls to achieve the patient's glycemic goals, treatment can be changed to daily insulin injections. Therapy should be intensified as needed with twice daily split/mL, ced insulin, three times daily insulin therapy, or multiple daily injections to achieve glycemic goals. :~ Rapid acting insulin is a new agent that is be ing used to achieve tight glycemic control in patients with type I diabetes: however, its role in type II diabetes is not yet defined.
Pregnancy and Preconception Counseling
Diabetes mellitus can significantly increase the risk of morbidity for the pregnant woman and the fetus or neo nate. l~n A significantly higher incidence of congenital anomalies occurs when maternal glycosylated hemoglobin in the first trimester is elevated, l:x The effects of precon ception care for diabetic mothers have been examined in nonrmldomized, clinical trials, and observational studies in patients with type I diabetes. These studies demon strate that preconception care for diabetic mothers cml reduce the incidence of malformations from approximately 9% to 2%, a rate similar to that observed in infants of mothers without diabetes. 12F~127
Because of the increased risks associated with suboptimal preconception care, type II diabetic women who are of childbearing potential should receive preconception counseling. Preconception counseling and optimization of glycemic control in women with diabetes mellitus results in optimal maternal and fetal outcomes. 1~-However, less than 20% of women with type I and type II diabetes re ceive prepregnancy care, 1:'" Women who are planning to become pregnant should be counseled regarding the in creased risks of pregnancy, the genetics of diabetes, the changes in lifestyle necessary (i.e., a personal commitment to diabetes care by the woman and family), and the possibility of hospitalization during pregnancy. Women not currently planning pregnancy require general information regarding the risks of pregnancy and the need for prepregnancy planning. The importance of preventing pregnancy by establishing an acceptable method of birth control should be emphasized.
In pregnant women with diabetes, specific attention should be given to diet mid exercise programs to allow adequate nutrition and optimal weight. As with all women contemplating pregnmlcy,130 folic acid (400 ~g/d) should be prescribed before pregnancy. Cessation of tobacco, alcohol, illicit drug, and caffeine use should be emphasized. In addition to usual prenatal care, the management plan should include discontinuation of oral hypoglycemics (which cross the placenta and cause severe hypoglyee mia) l~ and ACE inhibitors (which can be teratogenie) 131 and initiation of insulin therapy, with a plan of achieving blood glucose or GHb in the normal range.
Self-Management Education
At the time diabetes mellitus is diagnosed, the patient should be given extensive information about the disease Table 3 . Self-Management Topics* At each regular visit (e.g,, every 3~3 mos) ask about:
Active responsibility. Do you take active responsibility for your own daily diabetes care? (Demonstrate through words and actions that diabetes is a serious illness,) Glucose ~oal. Do you know your most recent glycos, ylated hemoglobin level and your progress toward your ~oal level? Blood glucose monitorin~ for patients on insulin. Do you know (1) the rationale for monitorin~ your blood glucose (sick day management, insulin dose adjustments), (2) your monitorin~ schedule, (3) as importmlt, nor is there scientific evidence that these brief discussions will lead to improved outcomes, They do.
however, represent content areas that have been identi fled as necessary to meet standards for diabetes education programs, znn that were based on an extensive review of the literature, XaS' and that are prudent and reasonable for a provider to address during a routine visit. 
CONCLUSIONS
